Literature DB >> 10920306

Molecular Papanicolaou tests in the twenty-first century: molecular analyses with fluid-based Papanicolaou technology.

W M Lin1, R Ashfaq, E A Michalopulos, A Maitra, A F Gazdar, C Y Muller.   

Abstract

OBJECTIVE: This study was undertaken to demonstrate the feasibility of performing molecular analyses at the deoxyribonucleic acid, ribonucleic acid and protein levels of cervical cytologic examination with a methanol fluid-based Papanicolaou specimen collection system. STUDY
DESIGN: Genomic deoxyribonucleic acid and total ribonucleic acid were extracted from cell pellets obtained from the residual fluid-based Papanicolaou specimen collection buffer after clinical processing. Genomic and human papillomavirus deoxyribonucleic acid polymerase chain reaction and reverse transcriptase-polymerase chain reaction were performed. Messenger ribonucleic acid transcript analysis and human papillomavirus 16 E6 mutational analysis were also performed. Methylation-specific polymerase chain reaction was used to evaluate hypermethylation status of the p16 gene and the gene for E-cadherin. Immunohistochemical staining for protein expression was performed on the processed monolayer slides.
RESULTS: Cell pellets from the residual fluid-based cytologic specimen yielded good quality deoxyribonucleic acid and ribonucleic acid. Molecular analyses of genomic deoxyribonucleic acid were successful for the identification of human papillomavirus E6 and p53 polymorphism status by means of restriction enzyme digestion and direct sequencing. Methylation status of the promotor regions of the p16 tumor suppressor gene and the gene for E-cadherin were also successfully identified. Ribonucleic acid was used as the template for transcript analysis and mutational analysis of the corresponding complementary deoxyribonucleic acid of the p53 gene. Protein expression analysis was demonstrated by immunohistochemical staining for carcinoembryonic antigen.
CONCLUSION: It is feasible to conduct multiple molecular analyses at the deoxyribonucleic acid, ribonucleic acid, and protein levels of the cervicovaginal cell pellets from the residual fluid-based Papanicolaou cytologic specimen. This relatively simple and widely used collection system will allow significant advances in molecular epidemiology and eventual development of a molecular Papanicolaou test.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10920306     DOI: 10.1067/mob.2000.105734

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Measurements of human papillomavirus transcripts by real time quantitative reverse transcription-polymerase chain reaction in samples collected for cervical cancer screening.

Authors:  Laurence Lamarcq; James Deeds; David Ginzinger; Jean Perry; Siddhartha Padmanabha; Karen Smith-McCune
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

2.  p16 expression in squamous lesions of the female genital tract.

Authors:  Mary M Finegan; Aaron C Han; Mitchell I Edelson; Norman G Rosenblum
Journal:  J Mol Histol       Date:  2004-02       Impact factor: 2.611

3.  Liquid based cytology: examination of its potential in a chlamydia screening programme.

Authors:  J Hopwood; H Mallinson; E Hodgson; L Hull
Journal:  Sex Transm Infect       Date:  2004-10       Impact factor: 3.519

4.  p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears.

Authors:  N Murphy; M Ring; A G Killalea; V Uhlmann; M O'Donovan; F Mulcahy; M Turner; E McGuinness; M Griffin; C Martin; O Sheils; J J O'Leary
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

5.  Papanicolaou tests and molecular analyses using new fluid-based specimen collection technology in 3000 Japanese women.

Authors:  N Masumoto; T Fujii; M Ishikawa; M Mukai; M Saito; T Iwata; T Fukuchi; K Kubushiro; K Tsukazaki; S Nozawa
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

6.  Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.

Authors:  Sonya Naryshkin; R Marshall Austin
Journal:  Drug Healthc Patient Saf       Date:  2012-11-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.